All In Biotech

Investigational drug · Phase 3

Velzatinib

Also called: GSK6042981

Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Gastrointestinal Neoplasms, Gastrointestinal Stromal Neoplasms.

Phase 3

Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

3

3 still active

All registered trials

8

Any phase or sponsor naming "Velzatinib"

First trial start

2026

Jul 27, 2026

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Velzatinib", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Gastrointestinal Neoplasms
  • Gastrointestinal Stromal Neoplasms

Approved drugs for the same conditions: Oncology · Gastroenterology and liver

Largest trials

Live from ClinicalTrials.gov: studies naming "Velzatinib" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 1 on PubMed

Also in development for Gastrointestinal Neoplasms

  • HS-20093Ris-Rez, Risvutatug rezetecanPhase 316 trials

    Hansoh BioMedical R&D Company · Neoplasms, Lung, Sarcoma, Osteosarcoma

  • IDRX-42velzatinib - subject to USAN approvalPhase 31 trial

    GSK · Gastrointestinal Neoplasms

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from GSK.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.